BMT CTN Protocol 1803 Haplo NK Cell

BMT CTN 1803 - Haplo-Identical Natural Killer (NK) Cells To Prevent Post-Transplant Relapse In AML and MDS (NK-REALM)

  • Key Personnel

             Co-Chair: Richard Champlin, MD rchampli@mdanderson.org

             Co-Chair: Sumithira Vasu, MBBS sumithira.vasu@osumc.edu

             Protocol Officer: Steven Devine, MD sdevine2@nmdp.org

             PRA Protocol Coordinator: Stacey Kloc klocstacey@prahs.com

             BMT CTN DCC Coordinator: Amy Foley afoley@nmdp.org

For the BMT CTN 1803 study, PRA Health Sciences is managing the study. The protocol, ICFs and other study materials are accessed via the PRA Health Sciences team; contact Stacey Kloc at klocstacey@prahs.com for details.